financetom
Business
financetom
/
Business
/
CenterPoint Energy Q3 adjusted EPS beats estimates, driven by regulatory recovery and reduced O&M
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CenterPoint Energy Q3 adjusted EPS beats estimates, driven by regulatory recovery and reduced O&M
Oct 23, 2025 3:53 AM

Overview

* CenterPoint Q3 non-GAAP EPS of $0.50 beats analyst expectations

* Q3 non-GAAP EPS increased over 60% year-over-year, driven by regulatory recovery and reduced O&M

* Company reiterates 2025 and 2026 non-GAAP EPS guidance, indicating continued growth

Outlook

* CenterPoint reiterates 2025 non-GAAP EPS guidance of $1.75-$1.77

* CenterPoint maintains 2026 non-GAAP EPS guidance of $1.89-$1.91

Result Drivers

* INDUSTRIAL THROUGHPUT - Houston Electric industrial throughput increased over 17% compared to Q3 2024, driving growth

* O&M EXPENSE REDUCTION - Significant reduction in O&M expenses contributed $0.12 per share favorability, primarily due to non-recurrence of storm restoration work

* TAX OPTIMIZATION - A one-time benefit related to tax optimization contributed $0.03 per share favorability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $0.50 $0.43

Adjusted (11

EPS Analysts

)

Q3 EPS $0.45

Q3 NET $293 mln

INCOME

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the multiline utilities peer group is "buy"

* Wall Street's median 12-month price target for CenterPoint Energy Inc ( CNP ) is $42.00, about 4.7% above its October 21 closing price of $40.03

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Jun 9, 2025
June 9 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.35 billion in its initial public offering in the United States. Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO
Jun 9, 2025
(Reuters) -Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.35 billion in its initial public offering in the United States. Irving, Texas-based Caris plans to raise up to $424 million by offering 23.5 million shares priced between $16 and $18 apiece. The IPO market is heating up as high-profile companies move...
Caris Life Sciences eyes up to $424 million raise in US IPO
Caris Life Sciences eyes up to $424 million raise in US IPO
Jun 9, 2025
June 9 (Reuters) - Precision medicine platform Caris Life Sciences said on Monday it was targeting to raise up to $423.5 million in its initial public offering in the United States. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved